Equities analysts expect that OraSure Technologies, Inc. (NASDAQ:OSUR) will post $0.03 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for OraSure Technologies’ earnings. The lowest EPS estimate is $0.02 and the highest is $0.03. OraSure Technologies posted earnings per share of $0.07 during the same quarter last year, which suggests a negative year over year growth rate of 57.1%. The business is expected to report its next quarterly earnings report on Wednesday, August 14th.
On average, analysts expect that OraSure Technologies will report full-year earnings of $0.23 per share for the current financial year, with EPS estimates ranging from $0.22 to $0.23. For the next year, analysts forecast that the company will report earnings of $0.33 per share, with EPS estimates ranging from $0.30 to $0.37. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for OraSure Technologies.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The firm had revenue of $30.12 million for the quarter, compared to analysts’ expectations of $29.66 million. OraSure Technologies had a net margin of 11.34% and a return on equity of 7.87%. The company’s revenue for the quarter was down 28.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.07 earnings per share.
In other OraSure Technologies news, SVP Jack E. Jerrett purchased 10,000 shares of OraSure Technologies stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of $8.55 per share, for a total transaction of $85,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stephen S. Phd Tang sold 16,667 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $11.10, for a total transaction of $185,003.70. Following the completion of the sale, the chief executive officer now owns 135,627 shares in the company, valued at approximately $1,505,459.70. The disclosure for this sale can be found here. In the last quarter, insiders have bought 21,000 shares of company stock worth $184,360. Company insiders own 1.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in OraSure Technologies by 2.4% in the first quarter. BlackRock Inc. now owns 9,118,245 shares of the medical instruments supplier’s stock worth $101,669,000 after purchasing an additional 215,993 shares during the last quarter. Renaissance Technologies LLC increased its position in OraSure Technologies by 5.0% in the first quarter. Renaissance Technologies LLC now owns 4,355,503 shares of the medical instruments supplier’s stock worth $48,564,000 after purchasing an additional 205,700 shares during the last quarter. Vanguard Group Inc. increased its position in OraSure Technologies by 1.5% in the third quarter. Vanguard Group Inc. now owns 3,576,389 shares of the medical instruments supplier’s stock worth $55,256,000 after purchasing an additional 53,671 shares during the last quarter. Dimensional Fund Advisors LP increased its position in OraSure Technologies by 8.4% in the first quarter. Dimensional Fund Advisors LP now owns 3,162,529 shares of the medical instruments supplier’s stock worth $35,262,000 after purchasing an additional 244,347 shares during the last quarter. Finally, American Capital Management Inc. increased its position in OraSure Technologies by 67.2% in the first quarter. American Capital Management Inc. now owns 2,876,592 shares of the medical instruments supplier’s stock worth $32,074,000 after purchasing an additional 1,156,560 shares during the last quarter. Institutional investors own 91.50% of the company’s stock.
Shares of OraSure Technologies stock traded up $0.10 on Friday, hitting $8.51. 424,345 shares of the company traded hands, compared to its average volume of 649,544. The stock has a market cap of $528.05 million, a P/E ratio of 17.02, a PEG ratio of 3.00 and a beta of 1.24. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.52 and a quick ratio of 6.56. OraSure Technologies has a 52 week low of $8.01 and a 52 week high of $17.97.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Recommended Story: Dead Cat Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.